Anti-Adalimumab Antibodies in Children With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis (ADA AIG-U)
Anti-Adalimumab Antibodies in a Prospective Cohort of Patients With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis: Incidence, Predictive Factors, and Clinical Correlations
This prospective, single-center observational cohort study aims to investigate the development of anti-Adalimumab antibodies in pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis initiating Adalimumab treatment.
The study will assess the frequency and timing of antibody development, identify potential predictive factors, including concomitant methotrexate treatment, and explore associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 patients will be enrolled and followed for 24 months. Clinical data and additional blood samples will be collected at baseline and at 3, 6, 12, 18, and 24 months during routine clinical visits.
Anti-Adalimumab antibodies and serum drug concentrations will be measured using surface plasmon resonance (SPR) technology. Treatment decisions will remain entirely based on routine clinical practice.
調査の概要
詳細な説明
Adalimumab is widely used in the treatment of juvenile idiopathic arthritis (JIA) and chronic non-infectious uveitis. Despite its established efficacy, some patients experience inadequate clinical response, secondary loss of efficacy, or disease flares during treatment. The development of anti-Adalimumab antibodies (AAA) may contribute to reduced serum drug concentrations and impaired therapeutic response. However, evidence regarding the incidence, timing, and clinical significance of AAA in paediatric patients remains limited and heterogeneous.
This prospective, single-centre, observational cohort study aims to investigate the development and kinetics of AAA in paediatric patients with JIA and/or chronic non-infectious uveitis initiating Adalimumab treatment. The study will also explore potential predictive factors for AAA development, including concomitant methotrexate therapy, and evaluate associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.
A total of 60 Adalimumab-naïve patients will be consecutively enrolled at AOU Meyer IRCCS, Florence, Italy. All participants will receive Adalimumab according to routine clinical practice, independently of study participation. No investigational treatment or study-related therapeutic intervention is planned.
Each participant will be followed for 24 months, with assessments at baseline and at 3, 6, 12, 18, and 24 months. Clinical and laboratory data will be collected during routine follow-up visits, including demographic characteristics, disease subtype and duration, concomitant treatments, disease activity measures, inflammatory markers, disease flares, and treatment modifications.
At each scheduled assessment, an additional 5 mL peripheral blood sample will be collected during routine blood sampling. Serum samples will be analysed at the PeptLab laboratory of the University of Florence using surface plasmon resonance (SPR) technology to determine AAA positivity and levels, as well as serum Adalimumab concentrations. AAA positivity will be defined according to a predefined threshold of 15 Response Units (RU).
The primary outcomes are the proportion of patients developing AAA during follow-up and the time from Adalimumab initiation to the first detection of AAA. Secondary outcomes include the identification of clinical and treatment-related factors associated with AAA development, changes in disease activity and functional assessment scores (JADAS-10 and CHAQ), inflammatory markers, occurrence and number of disease flares, and persistence of AAA positivity.
Statistical analyses will include descriptive and exploratory multivariable methods, longitudinal models for repeated measurements, and time-to-event analyses accounting for interval censoring when appropriate. Particular attention will be given to the potential association between concomitant methotrexate treatment and AAA development.
The overall study duration is expected to be 72 months, including 36 months of recruitment, individual follow-up, and final data analysis and reporting.
The study aims to improve understanding of Adalimumab immunogenicity in paediatric JIA and chronic non-infectious uveitis and to explore the potential clinical value of immunopharmacological monitoring in identifying patients at risk of secondary treatment failure or disease relapse.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:LUCIA PAOLINI
- 電話番号:390555662499
- メール:lucia.paolini@meyer.it
研究場所
-
-
-
Florence、イタリア
- 募集
- Aou Meyer IRCSS
-
コンタクト:
- LUCIA PAOLINI
- 電話番号:+390555662545
- メール:lucia.paolini@meyer.it
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis followed at the Pediatric Rheumatology Unit of AOU Meyer IRCCS, Florence, Italy, for whom initiation of Adalimumab treatment is clinically indicated.
Eligible patients must be Adalimumab-naïve and will be consecutively enrolled during routine outpatient or day-hospital visits. Treatment decisions will be made independently of study participation, according to standard clinical practice.
説明
Inclusion Criteria:
Age at diagnosis between 2 and 16 years.
Diagnosis of juvenile idiopathic arthritis (JIA) according to the International League of Associations for Rheumatology (ILAR) criteria, established on or after January 1, 2015, and/or diagnosis of chronic non-infectious uveitis according to the Standardization of Uveitis Nomenclature (SUN) Working Group criteria, established on or after January 1, 2015.
Clinical indication to initiate Adalimumab treatment in patients with no previous exposure to Adalimumab (Adalimumab-naïve), as determined by the treating physician.
Written informed consent from parents or legal guardians and assent from minors aged 7 years or older, where applicable.
Exclusion Criteria:
Age 18 years or older at enrollment.
Diagnoses other than juvenile idiopathic arthritis or chronic non-infectious uveitis.
Contraindications to Adalimumab, including tuberculosis exposure, history of multiple sclerosis or other demyelinating central nervous system disorders, or history of malignancy.
Previous exposure to Adalimumab before study enrollment.
Body weight below 12 kg.
Age below 24 months at enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Adalimumab-treated patients with JIA and/or chronic non-infectious uveitis
Pediatric patients diagnosed with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis who are initiating Adalimumab treatment according to routine clinical practice and have not previously received Adalimumab. Patients will be prospectively followed for 24 months, with clinical assessments and blood sample collection at baseline and at 3, 6, 12, 18, and 24 months to evaluate the development of anti-Adalimumab antibodies, serum drug concentrations, and clinical outcomes. |
Anti-Adalimumab Antibody and Serum Drug Level Assessment by SPR |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Patients Developing Anti-Adalimumab Antibodies
時間枠:Baseline and Months 3, 6, 12, 18, and 24
|
Proportion of patients with detectable anti-Adalimumab antibodies (AAA) during the 24-month follow-up, assessed using surface plasmon resonance (SPR). Antibody positivity will be defined using a predefined cut-off of 15 Response Units (RU). |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Time to Development of Anti-Adalimumab Antibodies
時間枠:From baseline to Month 24.
|
Time from initiation of Adalimumab treatment to the first detection of anti-Adalimumab antibodies, assessed at scheduled follow-up visits. The analysis will account for interval censoring between the last negative and first positive antibody determinations. |
From baseline to Month 24.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Factors Associated With Anti-Adalimumab Antibody Development
時間枠:Baseline to Month 24
|
Assessment of the association between anti-Adalimumab antibody (AAA) development and demographic, clinical, and laboratory factors, including sex, age, JIA subtype according to ILAR classification, disease duration, baseline inflammatory markers, and serum Adalimumab concentrations. |
Baseline to Month 24
|
|
Association Between Concomitant Methotrexate Treatment and AAA Development
時間枠:Baseline to Month 24
|
Assessment of the proportion of patients developing anti-Adalimumab antibodies according to concomitant methotrexate treatment (yes/no), including the time to antibody development where appropriate. |
Baseline to Month 24
|
|
Change in Juvenile Arthritis Disease Activity Score (JADAS-10)
時間枠:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in disease activity using the Juvenile Arthritis Disease Activity Score (JADAS-10) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Childhood Health Assessment Questionnaire (CHAQ) Score
時間枠:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in functional disability using the Childhood Health Assessment Questionnaire (CHAQ) during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Change in Inflammatory Markers (ESR and CRP)
時間枠:Baseline and Months 3, 6, 12, 18, and 24
|
Assessment of changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels during follow-up and their association with anti-Adalimumab antibody development. |
Baseline and Months 3, 6, 12, 18, and 24
|
|
Proportion of Patients Experiencing at Least One Disease Flare
時間枠:Baseline to Month 24
|
Proportion of patients experiencing at least one articular or ocular disease flare during the 24-month follow-up, according to the definitions established in the study protocol. |
Baseline to Month 24
|
|
Number of Disease Flares per Patient
時間枠:Baseline to Month 24
|
Total number of articular and/or ocular disease flares recorded for each patient during the 24-month follow-up period. |
Baseline to Month 24
|
|
Persistence of Anti-Adalimumab Antibody Positivity
時間枠:Baseline to Month 24
|
Proportion of anti-Adalimumab antibody-positive patients showing persistent antibody positivity, defined as two positive determinations performed at least six months apart. |
Baseline to Month 24
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- ADA AIG-U
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。